Results 221 to 222 of about 45,933 (222)

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors

Annals of Oncology, 2015
J R Infante, J C Bendell, D Rasco
exaly  

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†

Annals of Oncology, 2014
Patrick Neven, Mario Campone
exaly